The gut microbiome in intestinal fibrosis: Environmental protector or provocateur?

Science Translational Medicine

Volumn 5, Issue 190, 2013, Pages

  Rieder, Florian ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR ANTAGONIST; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ALCOHOL CONSUMPTION; CELL ACTIVATION; CHRONIC INFLAMMATION; ENTERITIS; ENVIRONMENTAL FACTOR; FOOD INTAKE; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; INTESTINAL FIBROSIS; INTESTINE FISTULA; INTESTINE FLORA; INTESTINE OBSTRUCTION; INTESTINE SURGERY; IRRITABLE COLON; MESENCHYME CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING;

ANIMALS; ENVIRONMENT; FIBROSIS; HUMANS; INTESTINES; MICROBIOTA;

EID: 84880516251     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3004731     Document Type: Review

References (60)

1. J. Cosnes, I. Nion-Larmurier, L. Beaugerie, P. Afchain, E. Tiret, J. P. Gendre, Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 54, 237-241 (2005).
2. R. G. Farmer, G. Whelan, V. W. Fazio, Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis. Gastroenterology 88, 1818-1825 (1985).
3. A. Armuzzi, G. Van Assche, W. Reinisch, G. Pineton de Chambrun, A. Griffiths, M. Sladek, J. C. Preiss, M. Lukas, G. D'Haens, Results of the 2nd scientific workshop of the ECCO (IV): Therapeutic strategies to enhance intestinal healing in infl ammatory bowel disease. J. Crohn's Colitis 6, 492-502 (2012).
4. L. Peyrin-Biroulet, A. Oussalah, N. Williet, C. Pillot, L. Bresler, M. A. Bigard, Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 60, 930-936 (2011).
5. S. L. Friedman, D. Sheppard, J. S. Duffield, S. Violette, Therapy for fibrotic diseases: Nearing the starting line. Sci. Transl. Med. 5, 167sr1 (2013).
6. F. Rieder, C. Fiocchi, Intestinal fibrosis in IBD - A dynamic, multifactorial process. Nat. Rev. Gastroenterol. Hepatol. 6, 228-235 (2009).
7. F. Rieder, J. Brenmoehl, S. Leeb, J. Schölmerich, G. Rogler, Wound healing and fibrosis in intestinal disease. Gut 56, 130-139 (2007).
8. S. M. Rappaport, Discovering environmental causes of disease. J. Epidemiol. Community Health 66, 99-102 (2012).
9. O. Takeuchi, S. Akira, Pattern recognition receptors and infl ammation. Cell 140, 805-820 (2010).
10. A. Uehara, H. Takada, Functional TLRs and NODs in human gingival fibroblasts. J. Dent. Res. 86, 249-254 (2007).
11. E. Seki, D. A. Brenner, Toll-like receptors and adaptor molecules in liver disease: Update. Hepatology 48, 322-335 (2008).
12. E. Seki, S. De Minicis, C. H. Osterreicher, J. Kluwe, Y. Osawa, D. A. Brenner, R. F. Schwabe, TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat. Med. 13, 1324-1332 (2007).
13. H. Miyazaki, R. Kobayashi, H. Ishikawa, N. Awano, S. Yamagoe, Y. Miyazaki, T. Matsumoto, Activation of COL1A2 promoter in human fibroblasts by Escherichia coli. FEMS Immunol. Med. Microbiol. 65, 481-487 (2012).
14. J. P. Burke, M. F. Cunningham, R. W. Watson, N. G. Docherty, J. C. Coffey, P. R. O'Connell, Bacterial lipopolysaccharide promotes profibrotic activation of intestinal fibroblasts. Br. J. Surg. 97, 1126-1134 (2010).
15. R. S. Lin, F. Y. Lee, S. D. Lee, Y. T. Tsai, H. C. Lin, R. H. Lu, W. C. Hsu, C. C. Huang, S. S. Wang, K. J. Lo, Endotoxemia in patients with chronic liver diseases: Relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J. Hepatol. 22, 165-172 (1995).
16. C. C. Chan, S. J. Hwang, F. Y. Lee, S. S. Wang, F. Y. Chang, C. P. Li, C. J. Chu, R. H. Lu, S. D. Lee, Prognostic value of plasma endotoxin levels in patients with cirrhosis. Scand. J. Gastroenterol. 32, 942-946 (1997).
17. J. M. Otte, I. M. Rosenberg, D. K. Podolsky, Intestinal myofibroblasts in innate immune responses of the intestine. Gastroenterology 124, 1866-1878 (2003).
18. F. Rieder, S. Bhilocha, A. Schirbel, Z. Ouyang, G. West, A. Atreja, H. Rho, C. De La Motte, C. Fiocchi, Activation of toll-like receptor (TLR) 5 induces a pro-fibrogenic phenotype on human intestinal myofibroblasts (HIF) - A novel pathway mediated by caspase 1. Gastroenterology 142, S114 (2011).
19. U. A. Hasan, G. Trinchieri, J. Vlach, Toll-like receptor signaling stimulates cell cycle entry and progression in fi- broblasts. J. Biol. Chem. 280, 20620-20627 (2005).
20. A. Eyking, B. Ey, M. Rünzi, A. I. Roig, H. Reis, K. W. Schmid, G. Gerken, D. K. Podolsky, E. Cario, Toll-like receptor 4 variant D299G induces features of neoplastic progression in Caco-2 intestinal cells and is associated with advanced human colon cancer. Gastroenterology 141, 2154-2165 (2011).
21. F. Rieder, S. Kessler, M. Sans, C. Fiocchi, Animal models of intestinal fibrosis: New tools for the understanding of pathogenesis and therapy of human disease. Am. J. Physiol. Gastrointest. Liver Physiol. 303, G786-G801 (2012).
22. J. B. Pucilowska, K. L. Williams, P. K. Lund, Fibrogenesis. IV. Fibrosis and infl ammatory bowel disease: Cellular mediators and animal models. Am. J. Physiol. Gastrointest. Liver Physiol. 279, G653-G659 (2000).
23. M. Mourelle, A. Salas, F. Guarner, E. Crespo, A. García- Lafuente, J. R. Malagelada, Stimulation of transforming growth factor beta1 by enteric bacteria in the pathogenesis of rat intestinal fibrosis. Gastroenterology 114, 519-526 (1998).
24. A. Franke, D. P. McGovern, J. C. Barrett, K. Wang, G. L. Radford-Smith, T. Ahmad, C. W. Lees, T. Balschun, J. Lee, R. Roberts, C. A. Anderson, J. C. Bis, S. Bumpstead, D. Ellinghaus, E. M. Festen, M. Georges, T. Green, T. Haritunians, L. Jostins, A. Latiano, C. G. Mathew, G. W. Montgomery, N. J. Prescott, S. Raychaudhuri, J. I. Rotter, P. Schumm, Y. Sharma, L. A. Simms, K. D. Taylor, D. Whiteman, C. Wijmenga, R. N. Baldassano, M. Barclay, T. M. Bayless, S. Brand, C. Büning, A. Cohen, J. F. Colombel, M. Cottone, L. Stronati, T. Denson, M. De Vos, R. D'Inca, M. Dubinsky, C. Edwards, T. Florin, D. Franchimont, R. Gearry, J. Glas, A. Van Gossum, S. L. Guthery, J. Halfvarson, H. W. Verspaget, J. P. Hugot, A. Karban, D. Laukens, I. Lawrance, M. Lemann, A. Levine, C. Libioulle, E. Louis, C. Mowat, W. Newman, J. Panés, A. Phillips, D. D. Proctor, M. Regueiro, R. Russell, P. Rutgeerts, J. Sanderson, M. Sans, F. Seibold, A. H. Steinhart, P. C. Stokkers, L. Torkvist, G. Kullak-Ublick, D. Wilson, T. Walters, S. R. Targan, S. R. Brant, J. D. Rioux, M. D'Amato, R. K. Weersma, S. Kugathasan, A. M. Griffiths, J. C. Mansfield, S. Vermeire, R. H. Duerr, M. S. Silverberg, J. Satsangi, S. Schreiber, J. H. Cho, V. Annese, H. Hakonarson, M. J. Daly, M. Parkes, Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat. Genet. 42, 1118-1125 (2010).
25. J. Adler, S. C. Rangwalla, B. A. Dwamena, P. D. Higgins, The prognostic power of the NOD2 genotype for complicated Crohn's disease: A meta-analysis. Am. J. Gastroenterol. 106, 699-712 (2011).
26. R. K. Weersma, P. C. Stokkers, I. Cleynen, S. C. Wolfkamp, L. Henckaerts, S. Schreiber, G. Dijkstra, A. Franke, I. M. Nolte, P. Rutgeerts, C. Wijmenga, S. Vermeire, Confirmation of multiple Crohn's disease susceptibility loci in a large Dutch-Belgian cohort. Am. J. Gastroenterol. 104, 630-638 (2009).
27. D. N. Frank, C. E. Robertson, C. M. Hamm, Z. Kpadeh, T. Zhang, H. Chen, W. Zhu, R. B. Sartor, E. C. Boedeker, N. Harpaz, N. R. Pace, E. Li, Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in infl ammatory bowel diseases. Infamm. Bowel Dis. 17, 179-184 (2011).
28. H. Sokol, C. Lay, P. Seksik, G. W. Tannock, Analysis of bacterial bowel communities of IBD patients: What has it revealed? Inf amm. Bowel Dis. 14, 858-867 (2008).
29. F. Rieder, I. C. Lawrance, A. Leite, M. Sans, Predictors of fibrostenotic Crohn's disease. Inf amm. Bowel Dis. 17, 2000-2007 (2011).
30. S. Swaminathan, S. V. Shah, New insights into nephrogenic systemic fibrosis. J. Am. Soc. Nephrol. 18, 2636-2643 (2007).
31. M. J. Wood, L. W. Powell, G. A. Ramm, Environmental and genetic modifiers of the progression to fibrosis and cirrhosis in hemochromatosis. Blood 111, 4456-4462 (2008).
32. R. Barouki, X. Coumoul, P. M. Fernandez-Salguero, The aryl hydrocarbon receptor, more than a xenobiotic-interacting protein. FEBS Lett. 581, 3608-3615 (2007).
33. G. M. Lehmann, X. Xi, A. A. Kulkarni, K. C. Olsen, S. J. Pollock, C. J. Baglole, S. Gupta, A. E. Casey, K. R. Huxlin, P. J. Sime, S. E. Feldon, R. P. Phipps, The aryl hydrocarbon receptor ligand ITE inhibits TGF® 1-induced human myofibroblast differentiation. Am. J. Pathol. 178, 1556-1567 (2011).
34. T. C. Peterson, P. Hodgson, P. Fernandez-Salguero, M. Neumeister, F. J. Gonzalez, Hepatic fibrosis and cytochrome P450: Experimental models of fibrosis compared to AHR knockout mice. Hepatol. Res. 17, 112-125 (2000).
35. J. Mimura, Y. Fujii-Kuriyama, Functional role of AhR in the expression of toxic effects by TCDD. Biochim. Biophys. Acta 1619, 263-268 (2003).
36. I. Monteleone, A. Rizzo, M. Sarra, G. Sica, P. Sileri, L. Biancone, T. T. MacDonald, F. Pallone, G. Monteleone, Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit infl ammation in the gastrointestinal tract. Gastroenterology 141, 237-248, e1 (2011).
37. Y. Li, S. Innocentin, D. R. Withers, N. A. Roberts, A. R. Gallagher, E. F. Grigorieva, C. Wilhelm, M. Veldhoen, Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. Cell 147, 629-640 (2011).
38. L. A. Johnson, A. Luke, K. Sauder, D. S. Moons, J. C. Horowitz, P. D. Higgins, Intestinal fibrosis is reduced by early elimination of infl ammation in a mouse model of IBD: Impact of a "Top-Down" approach to intestinal fibrosis in mice. Inf amm. Bowel Dis. 18, 460-471 (2012).
39. B. G. Feagan, R. Panaccione, W. J. Sandborn, G. R. D'Haens, S. Schreiber, P. J. Rutgeerts, E. V. Loftus, Jr, K. G. Lomax, A. P. Yu, E. Q. Wu, J. Chao, P. Mulani, Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: Results from the CHARM study. Gastroenterology 135, 1493-1499 (2008).
40. S. Kugathasan, L. J. Saubermann, L. Smith, D. Kou, J. Itoh, D. G. Binion, A. D. Levine, R. S. Blumberg, C. Fiocchi, Mucosal T-cell immunoregulation varies in early and late infl ammatory bowel disease. Gut 56, 1696-1705 (2007).
41. R. G. Wells, The role of matrix stiffness in regulating cell behavior. Hepatology 47, 1394-1400 (2008).
42. S. N. Flier, H. Tanjore, E. G. Kokkotou, H. Sugimoto, M. Zeisberg, R. Kalluri, Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis. J. Biol. Chem. 285, 20202-20212 (2010).
43. F. Rieder, S. P. Kessler, G. A. West, S. Bhilocha, C. de la Motte, T. M. Sadler, B. Gopalan, E. Stylianou, C. Fiocchi, Infl ammation-induced endothelial-to-mesenchymal transition: A novel mechanism of intestinal fibrosis. Am. J. Pathol. 179, 2660-2673 (2011).
44. H. Uehara, T. Nakagawa, T. Katsuno, T. Sato, A. Isono, Y. Noguchi, Y. Saito, Emergence of fibrocytes showing morphological changes in the infl amed colonic mucosa. Dig. Dis. Sci. 55, 253-260 (2010).
45. I. C. Lawrance, L. Maxwell, W. Doe, Altered response of intestinal mucosal fibroblasts to profibrogenic cytokines in infl ammatory bowel disease. Inf amm. Bowel Dis. 7, 226-236 (2001).
46. J. Dammeier, M. Brauchle, W. Falk, G. R. Grotendorst, S. Werner, Connective tissue growth factor: A novel regulator of mucosal repair and fibrosis in infl ammatory bowel disease? Int. J. Biochem. Cell Biol. 30, 909-922 (1998).
47. M. W. Babyatsky, G. Rossiter, D. K. Podolsky, Expression of transforming growth factors alpha and beta in colonic mucosa in infl ammatory bowel disease. Gastroenterology 110, 975-984 (1996).
48. I. C. Lawrance, L. Maxwell, W. Doe, Infl ammation location, but not type, determines the increase in TGF-beta1 and IGF-1 expression and collagen deposition in IBD intestine. Inf amm. Bowel Dis. 7, 16-26 (2001).
49. S. Kumagai, H. Ohtani, T. Nagai, K. Funa, N. O. Hiwatashi, H. Shimosegawa, H. Nagura, Platelet-derived growth factor and its receptors are expressed in areas of both active infl ammation and active fibrosis in infl ammatory bowel disease. Tohoku J. Exp. Med. 195, 21-33 (2001).
50. M. Eivindson, H. Grønbaek, A. Flyvbjerg, J. Frystyk, E. Zimmermann- Nielsen, J. F. Dahlerup, The insulin-like growth factor (IGF)-system in active ulcerative colitis and Crohn's disease: Relations to disease activity and corticosteroid treatment. Growth Horm. IGF Res. 17, 33-40 (2007).
51. P. Hoffmann, M. Reinshagen, J. M. Zeeh, J. Lakshmanan, V. S. Wu, H. Goebell, G. Gerken, V. E. Eysselein, Increased expression of epidermal growth factor-receptor in an experimental model of colitis in rats. Scand. J. Gastroenterol. 35, 1174-1180 (2000).
52. S. Fichtner-Feigl, W. Strober, K. Kawakami, R. K. Puri, A. Kitani, IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fi- brosis. Nat. Med. 12, 99-106 (2006).
53. D. M. Spencer, G. M. Veldman, S. Banerjee, J. Willis, A. D. Levine, Distinct infl ammatory mechanisms mediate early versus late colitis in mice. Gastroenterology 122, 94-105 (2002).
54. F. Cominelli, C. C. Nast, B. D. Clark, R. Schindler, R. Lierena, V. E. Eysselein, R. C. Thompson, C. A. Dinarello, Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J. Clin. Invest. 86, 972-980 (1990).
55. S. Fichtner-Feigl, W. Strober, E. K. Geissler, H. J. Schlitt, Cytokines mediating the induction of chronic colitis and colitis-associated fibrosis. Mucosal Immunol. 1, (suppl. 1), S24-S27 (2008).
56. Y. Motomura, W. I. Khan, R. T. El-Sharkawy, M. Verma- Gandhu, E. F. Verdu, J. Gauldie, S. M. Collins, Induction of a fibrogenic response in mouse colon by overexpression of monocyte chemoattractant protein 1. Gut 55, 662-670 (2006).
57. K. A. Papadakis, S. R. Targan, The role of chemokines and chemokine receptors in mucosal infl ammation. Infamm. Bowel Dis. 6, 303-313 (2000).
58. G. A. Grassl, Y. Valdez, K. S. Bergstrom, B. A. Vallance, B. B. Finlay, Chronic enteric salmonella infection in mice leads to severe and persistent intestinal fibrosis. Gastroenterology 134, 768-780, e2 (2008).
59. G. G. Vaday, O. Lider, Extracellular matrix moieties, cytokines, and enzymes: Dynamic effects on immune cell behavior and infl ammation. J. Leukoc. Biol. 67, 149-159 (2000).
60. H. Schor, G. G. Vaday, O. Lider, Modulation of leukocyte behavior by an infl amed extracellular matrix. Dev. Immunol. 7, 227-238 (2000).